Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03488693 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

Study acronym: TAILOR RT
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 65 record versions are listed below. See every version on ClinicalTrials.gov ↗

  1. Trial status changed: Recruiting → Active, Not Recruiting
    • Enrollment target: estimated 2140 to confirmed 2138
    • Site details revised at 485 of 485 sites
    v65
  2. Site details revised at 13 of 485 sitesv64
  3. Study sites: 483 to 485v63
  4. Trial sites expanded: 475 → 483 locationsv62
  5. Study sites: 472 to 475v61
Show 45 earlier versionsHide 45 earlier versions
  1. Study sites: 464 to 472v60
  2. Study sites: 462 to 464v59
  3. Study sites: 461 to 462v58
  4. Study sites: 455 to 461v57
  5. Study sites: 449 to 455v56
  6. Study sites: 447 to 449v55
  7. Study sites: 442 to 447v54
  8. Study sites: 438 to 442v53
  9. Study sites: 436 to 438v52
  10. Study sites: 433 to 436v51
  11. Study sites: 423 to 433v50
  12. Re-verified, no change to tracked fieldsv49
  13. Study sites: 374 to 423v48
  14. Start date: May 30, 2018 to Oct 16, 2018v47
  15. Eligibility criteria expanded, about 3 wordsv46
  16. Study sites: 357 to 374v45
  17. Site details revised at 14 of 357 sitesv44
  18. Study sites: 347 to 357v43
  19. Study sites: 342 to 347v42
  20. Study sites: 331 to 342v41
  21. Study sites: 322 to 331v40
  22. Study sites: 314 to 322v39
  23. Study sites: 312 to 314v38
  24. Eligibility criteria shortened, about 1 wordv37
  25. Study sites: 306 to 312v36
  26. Study sites: 303 to 306v35
  27. Study sites: 299 to 303v34
  28. Site details revised at 11 of 299 sitesv33
  29. Phase: Not applicable to Phase 3v32
  30. Study sites: 295 to 299
    • Eligibility criteria expanded, about 125 words
    • Study title expanded, about 1 word
    v31
  31. Study sites: 292 to 295v30
  32. Re-verified, no change to tracked fieldsv29
  33. Study sites: 287 to 292v28
  34. Study sites: 283 to 287v27
  35. Study sites: 280 to 283v26
  36. Study sites: 277 to 280v25
  37. Study sites: 273 to 277v24
  38. Study sites: 272 to 273v23
  39. Study sites: 267 to 272v22
  40. Study sites: 263 to 267v21
  41. Study sites: 250 to 263v20
  42. Re-verified, no change to tracked fieldsv19
  43. Study sites: 232 to 250v18
  44. Study sites: 226 to 232v17
  45. Study sites: 221 to 226v16
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
Trial Details
NCT Number NCT03488693
Lead Sponsor Canadian Cancer Trials Group
Collaborators: Alliance for Clinical Trials in Oncology, Eastern Cooperative Oncology Group, NRG Oncology, SWOG Cancer Research Network
Conditions
(from sponsor)		 Breast Cancer
Related terms Breast Neoplasms
Enrollment 2,138 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov